BAFF

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Retrieved on: 
金曜日, 6月 14, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, IL-17A, Congress, BAFF, News, Patient, Standard of care, Mouse, T helper cell, Inflammation, Poster, Autoimmunity, Interleukin, Rheumatoid arthritis, EULAR, Antibody, Vaccine

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren’s syndrome.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren’s syndrome.
  • These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Congress of Rheumatology (EULAR) 2024 in Vienna.
  • “The results in Sjogren’s syndrome demonstrate that tibulizumab achieved robust target engagement, nearing maximum serum levels following single, well-tolerated subcutaneous doses at four-week intervals.
  • Twenty-one participants in the 12-week study received ≥1 dose of tibulizumab (30mg Q4W, 100mg Q4W, 300mg Q4W, 300mg Q2W), with four receiving placebo.

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Retrieved on: 
木曜日, 6月 6, 2024
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, BAFF, Amgen, Maryland School, Patient, University of California, Berkeley, Methotrexate, Multiple sclerosis, Benaroya Research Institute, Caregiver, Biogen, Harvard Medical School, Dermatology, Rheumatoid arthritis, School, Atopic dermatitis, Dinesh Khanna, UCLA, University college, Eli Lilly and Company, University, Scleroderma, UC, Executive, Lichen planus, Lupus, Bangladesh Technical Education Board, Translational medicine, National Institutes of Health, Immunology, Hidradenitis suppurativa, Rheumatology, Disorder, Associate, Inflammation, Hospital, Molecular biology, Psoriasis, Clinical research, Doctor of Philosophy, Lilly, Diagnosis, BRI, SAB, Psoriatic arthritis, Vasculitis, Autoimmunity, Knowledge, Pharmaceutical industry

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the formation of a Scientific Advisory Board (SAB) with leading experts from rheumatology, dermatology, and immunology.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the formation of a Scientific Advisory Board (SAB) with leading experts from rheumatology, dermatology, and immunology.
  • The five distinguished founding members of the SAB are Johann Gudjonsson, M.D, Ph.D., Dinesh Khanna, M.D., M.Sc., Ajay Nirula, M.D., Ph.D., Michael Weinblatt, M.D.
  • “We welcome these esteemed advisors whose expertise will enhance our understanding of targeted pathways and their pivotal role in disease pathogenesis.
  • Dinesh Khanna, M.D., M.Sc., is a Professor of Medicine and serves as the Director of the University of Michigan Scleroderma Program.

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Retrieved on: 
火曜日, 6月 4, 2024
Managed Care, Biotechnology, Pharmaceutical, Health, BAFF, B-cell activating factor, Capital market, AGM, Patient, Name, Glass Lewis, Growth, Letter, Membrane protein, Investment, FDA, Jefferies, B cell, RBC Capital Markets, Management

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued the following letter to shareholders in response to a letter from Lucien Selce.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued the following letter to shareholders in response to a letter from Lucien Selce.
  • However, the recent letter from Lucien Selce lacks substance and many of his ideas and criticisms are not grounded in facts.
  • Despite having ample opportunity to propose alternative directors as part of this year’s proxy process, Mr. Selce failed to do so.
  • If Mr. Selce were serious about his proposals or experienced in corporate governance best practices, he would provide specificity and actionable steps.

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

Retrieved on: 
月曜日, 6月 3, 2024
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Autoimmunity, IL-17A, EULAR, News, Sjögren syndrome, Inflammation, Rheumatoid arthritis, Poster, Translational medicine, BAFF

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data from its tibulizumab (ZB-106) program exploring the clinical potential of the dual-pathway antibody in Sjogren's syndrome and rheumatoid arthritis (RA) at EULAR 2024, June 12-15 in Vienna.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data from its tibulizumab (ZB-106) program exploring the clinical potential of the dual-pathway antibody in Sjogren's syndrome and rheumatoid arthritis (RA) at EULAR 2024, June 12-15 in Vienna.
  • “We believe that dual-pathway inhibition may warrant broad clinical exploration and help define the expanding potential of ZB-106 across a portfolio of autoimmune diseases.”
    Zura Bio will present results as detailed below.
  • The poster will be available on the Zura Bio website in the News and Events section and archived for at least 30 days following presentation.
  • Abstract, accepted for publication only, is available here on the EULAR 2024 website.

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Retrieved on: 
水曜日, 4月 10, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Slate, Glomerulonephritis, FASN, Lazard, Lupus nephritis, Kidney, Immunotherapy, BAFF, Centerview Partners, Immunoglobulin A, Autoimmune disease, Hart–Scott–Rodino Antitrust Improvements Act, Patient, Multimedia, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
  • The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.
  • A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
  • For Alpine, Centerview Partners is acting as exclusive financial advisor and Fenwick & West LLP as legal counsel.

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

Retrieved on: 
水曜日, 4月 10, 2024
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Congress, Immunoglobulin G, ALPN, University, Glomerular filtration rate, Proteinuria, Survival, Cytokine, MD, Hematuria, UPCR, Webcast, Immunoglobulin A, EGFR, Disease, Nephrology, Patient, WCN, Alpine, Inflammation, Multimedia, Infection, Biomarker, Exhibition, University of Leicester, Autoimmunity, BAFF, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.
  • RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, where povetacicept is administered subcutaneously (SC) once every four weeks.
  • As of March 01, 2024, 41 patients with IgAN had received povetacicept 80 or 240 mg subcutaneously every 4 weeks.
  • These data strongly support the inhibition of APRIL/BAFF pathways by povetacicept and its efficacy in the treatment of IgAN as well as the need for further clinical development.

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Retrieved on: 
水曜日, 4月 10, 2024
Research, Infectious Diseases, Hospitals, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Slate, Glomerulonephritis, FASN, Lazard, Lupus nephritis, Kidney, Immunotherapy, BAFF, Centerview Partners, Immunoglobulin A, Autoimmune disease, Hart–Scott–Rodino Antitrust Improvements Act, Patient, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
  • The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.
  • A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
  • For Alpine, Centerview Partners is acting as exclusive financial advisor and Fenwick & West LLP as legal counsel.

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Retrieved on: 
木曜日, 3月 28, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, IL-17A, Administration, Ulcerative colitis, Congress, Thymic stromal lymphopoietin, Atopic dermatitis, Alopecia areata, Inflammation, Chronic obstructive pulmonary disease, Allergy, TSLP, BCA, CMC, G&A, Interleukin 7, Benaroya Research Institute, Business analyst, Abstract, Asthma, IL-7, Research and development, Drug development, Senior management, BAFF, Eli Lilly and Company, Translational medicine, Autoimmunity, Management

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
  • The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D.
  • Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer.
  • Dr. Sidhu continued, "On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer.

Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results

Retrieved on: 
月曜日, 3月 18, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Research program, Administration, Congress, Development, WT, Lupus, Patient, Immunoglobulin A, Glomerular filtration rate, SLE, Inflammation, MD, UPCR, Neonatal Fc receptor, American College, Investment, Clinical trial, Society, EGFR, Nephrology, BAFF, Proteinuria, Immunoglobulin G, Autoimmunity, ALPN, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.
  • “2023 was a transformational year for Alpine, with initial IgA nephropathy (IgAN) data presented at the American Society of Nephrology Kidney Week 2023 suggesting a best-in-class profile for povetacicept, our next-generation dual BAFF/APRIL inhibitor.
  • In addition, povetacicept was well tolerated during subcutaneous administration, with no instances of IgG
  • Net Loss: Net loss for the year ended December 31, 2023, was $32.2 million compared to $57.8 million for the same period in 2022.

Black Alphabet NFP Expands Outreach with Free Art Therapy Programs and a New Community Arts Space

Retrieved on: 
火曜日, 1月 16, 2024
Culture, McMath, BAFF, Silver, Mental health

CHICAGO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Black Alphabet NFP, an organization championing the Black LGBTQ+ community's empowerment, proudly announces its latest initiatives. These include the introduction of free art therapy programs in Chicago and the surrounding suburbs and the upcoming launch of a new community arts space. This endeavor builds on Black Alphabet's reputation, established through its flagship program, Black Alphabet Film Festival (BAFF), which showcases the diversity and talent within the Black LGBTQ+ community.

Key Points: 
  • CHICAGO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Black Alphabet NFP, an organization championing the Black LGBTQ+ community's empowerment, proudly announces its latest initiatives.
  • These include the introduction of free art therapy programs in Chicago and the surrounding suburbs and the upcoming launch of a new community arts space.
  • This endeavor builds on Black Alphabet's reputation, established through its flagship program, Black Alphabet Film Festival (BAFF), which showcases the diversity and talent within the Black LGBTQ+ community.
  • These art therapy programs and our new arts space reflect our dedication to offering creative and supportive environments for expression and healing."